@article {Fafi-Kremer2020.05.19.20101832, author = {Samira Fafi-Kremer and Timoth{\'e}e Bruel and Yoann Madec and Rebecca Grant and Laura Tondeur and Ludivine Grzelak and Isabelle Staropoli and Fran{\c c}ois Anna and Philippe Souque and Catherine Schmidt-Mutter and Nicolas Collongues and Alexandre Bolle and Aur{\'e}lie Velay and Nicolas Lefebvre and Marie Mielcarek and Nicolas Meyer and David Rey and Pierre Charneau and Bruno Hoen and J{\'e}r{\^o}me De Seze and Olivier Schwartz and Arnaud Fontanet}, title = {Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France}, elocation-id = {2020.05.19.20101832}, year = {2020}, doi = {10.1101/2020.05.19.20101832}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background The serologic response of individuals with mild forms of SARS-CoV-2 infection is poorly characterized.Methods Hospital staff who had recovered from mild forms of PCR-confirmed SARS-CoV-2 infection were tested for anti-SARS-CoV-2 antibodies using two assays: a rapid immunodiagnostic test (99.4\% specificity) and the S-Flow assay (\~{}99\% specificity).The neutralizing activity of the sera was tested with a pseudovirus-based assay.Results Of 162 hospital staff who participated in the investigation, 160 reported SARS-CoV-2 infection that had not required hospital admission and were included in these analyses. The median time from symptom onset to blood sample collection was 24 days (IQR: 21{\textendash}28, range 13{\textendash}39). The rapid immunodiagnostic test detected antibodies in 153 (95.6\%) of the samples and the S-Flow assay in 159 (99.4\%), failing to detect antibodies in one sample collected 18 days after symptom onset (the rapid test did not detect antibodies in that patient). Neutralizing antibodies (NAbs) were detected in 79\%, 92\% and 98\% of samples collected 13{\textendash}20, 21{\textendash}27 and 28{\textendash}41 days after symptom onset, respectively (P=0.02).Conclusion Antibodies against SARS-CoV-2 were detected in virtually all hospital staff sampled from 13 days after the onset of COVID-19 symptoms. This finding supports the use of serologic testing for the diagnosis of individuals who have recovered from SARS-CoV-2 infection. The neutralizing activity of the antibodies increased overtime. Future studies will help assess the persistence of the humoral response and its associated neutralization capacity in recovered patients.Competing Interest StatementSFK, TB, YM, RG, LT, LG, IS, FA, PS, CSM, NC, AB, AV, NL, MM, NM, DR, BH, JDS, OS and AF have no competing interest to declare. PC is the founder and CSO of TheraVectys.Clinical TrialNCT04325646Funding StatementOS lab is funded by Institut Pasteur, ANRS, Sidaction, the Vaccine Research Institute (ANR- 10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), {\textquotedblleft}TIMTAMDEN{\textquotedblright} ANR-14-CE14-0029, {\textquotedblleft}CHIKV-Viro- Immuno{\textquotedblright} ANR-14-CE14-0015-01 and the Gilead HIV cure program. LG is supported by the French Ministry of Higher Education, Research and Innovation. AF lab is funded by Labex IBEID (ANR-10-LABX-62-IBEID) and the INCEPTION project (PIA/ANR-16-CONV-0005). SFK lab receives funding from Strasbourg University Hospitals (COVID-HUS ; CE-2020-34)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was registered with ClinicalTrials.gov (NCT04325646) and received ethical approval by the Comite de Protection des Personnes Ile de France III. Informed consent was obtained from all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article (and its supplementary information files).}, URL = {https://www.medrxiv.org/content/early/2020/05/22/2020.05.19.20101832.1}, eprint = {https://www.medrxiv.org/content/early/2020/05/22/2020.05.19.20101832.1.full.pdf}, journal = {medRxiv} }